Diacylglycerol acyl transferase 2 inhibitors
Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
1. A method for treating hyperlipidemia, dyslipidemia,
atherosclerosis, hypertriglyceridemia, or hyper apo B lipoproteinemia, in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of a compound according to Formula (I) or a pharmaceutically acceptable salt of said compound;
wherein
D 1 and D 2 are each independently N or CH;
R 1 is H, or (C 1 -C 2 )alkyl optionally substituted with one or two substituents each independently selected from fluoro and (C 3 -C 6 )cycloalkyl;
R 2 is H or fluoro;
R 3 is,
R 4 is H, cyano, or (C 1 -C 4 )alkyl optionally substituted with one or two substituents each independently selected from —OH and —S(O) 2 R 6 ;
R 5 is H or —OH, and
R 6 is (C 1 -C 4 )alkyl.
2. A method for treating Type II diabetes mellitus, early-onset Type 2 diabetes (EOD), conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, metabolic syndrome, syndrome X, hyperglycemia, hyperinsulinemia, insulin resistance, or impaired glucose metabolism, in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of a compound according to Formula (I) or a pharmaceutically acceptable salt of said compound;
wherein
D 1 and D 2 are each independently N or CH;
R 1 is H, or (C 1 -C 2 )alkyl optionally substituted with one or two substituents each independently selected from fluoro and (C 3 -C 6 )cycloalkyl,
R 2 is H or fluoro;
R 3 is,
R 4 is H, cyano, or (C 1 -C 4 )alkyl optionally substituted with one or two substituents each independently selected from —OH and —S(O) 2 R 6 ;
R 5 is H or —OH; and
R 6 is (C 1 -C 4 )alkyl.
3. The method of claim 1 wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.
4. The method of claim 2 wherein the compound of Formula (I) is
or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 wherein the compound of Formula (I) is
6. The method of claim 2 wherein the compound of Formula (I) is
7. The method of claim 1 wherein the compound of Formula (I) is 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof.
8. The method of claim 2 wherein the compound of Formula (I) is 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 wherein the compound of Formula (I) is 2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide.
10. The method of claim 2 wherein the compound of Formula (I) is 2-(5-((3-ethoxpyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide.